Allie Nawrat

You can get in touch with Allie on Alexandra.Nawrat@verdict.co.uk

All articles by Allie Nawrat

1. Researchers discover antibody that interacts with norovirus strains

   Scientists from two US universities have identified an antibody that inhibits multiple strains of norovirus, a serious stomach virus responsible…
   Read More…

   19 Jun
2. Researchers discover how to identify exhausted T cells due to infection

   Researchers from the Perelman University of Medicine, University of Pennsylvania, have discovered that the TOX protein plays a crucial role…
   Read More…

   18 Jun
3. Janssen’s Tremfya shows promise in two Phase III psoriatic arthritis trials

   Johnson & Johnson subsidiary Janssen has announced that Tremfya (guselkumab) reached its primary endpoint in the Phase III DISCOVER one…
   Read More…

   17 Jun
4. FDA chooses IBM, KMPG, Merck and Walmart for pharma blockchain pilot

   The US Food and Drug Administration (FDA) has chosen IBM, Merck, KPMG and Walmart to support its latest Drug Supply…
   Read More…

   14 Jun
5. BMS’ Opdivo plus Yervoy for RCC to be available through NHS Scotland

   Scotland’s healthcare pricing regulator the Scottish Medicines Consortium (SMC) has decided to fund Bristol-Myers Squibb (BMS)’s Opdivo (nivolumab) plus Yervoy…
   Read More…

   11 Jun
6. Diabetes Week: investigating the immune basis of type 1 diabetes

   Approximately 422 million people have diabetes globally, which represents around 8.5% of adults in the world. It was directly responsible…
   Read More…

   10 Jun
7. Everest Medicines to commercialise Calliditas’ Nefecon in Greater China and Singapore

   Sweden-based Calliditas Therapeutics has announced that Everest Medicines will commercialise its IgA nephropathy (IgAN) drug Nefecon in Greater China, which…
   Read More…

   10 Jun
8. Medidata: moving towards virtualised, patient-centric trials

   Centring around its mission station of “powering smarter treatment and healthier people”, Medidata’s Rave platform supports companies and researchers throughout…
   Read More…

   10 Jun
9. AstraZeneca’s Calquence shows superiority to chemotherapy in CLL

   AstraZeneca has announced Calquence (acalabrutinib) reached both its primary and secondary endpoints in chronic lymphocytic leukaemia (CLL). In preliminary analysis…
   Read More…

   7 Jun
10. Researchers discover new drug target in tuberculosis

    Researchers have identified group 3 innate lymphoid cells (ILC3) as the coordinators of the immune response immediately following infection with…
    Read More…

    6 Jun